# US 12,178,841 B2 · Treatment of non-cystic fibrosis bronchiectasis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,841 B2
- Document ID: US12178841B2
- Status: Granted
- Kind: B2
- Application number: 17/394,487
- Filed: 2021-08-05
- Published: 2023-02-16
- Granted: 2024-12-31
- Earliest claimed: 2021-08-05
- Assignees: Zambon S.p.A.
- Applicants: Zambon S.P.A.
- Inventors: Paola Castellani
- Web page: https://patentgrep.com/patent/US12178841B2

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB) by administering colistin is described.

## Claims

### Claim 1

A method of reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB) and P. aeruginosa infections, said method comprising:
administering by inhalation to said patients a dose of from 20 mg Colistin Based Activity (CBA) as colistimethate sodium (CMS) a day to 60 mg CBA as CMS/day; and
reducing said frequency of said pulmonary exacerbations in said patients, wherein said patients had at least two NCFB pulmonary exacerbations requiring oral or inhaled antibiotics or one NCFB pulmonary exacerbation requiring intravenous antibiotics in the 12 months preceding the inhalatory CMS administration and wherein said patients did not have any NCFB pulmonary exacerbation for at least 30 days before the beginning of the inhalatory CMS administration.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said dose is of from 10 mg CBA to 30 mg CBA twice a day.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said dose is 10 mg CBA twice a day.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said CMS is administered for at least 12 months.

### Claim 5 (depends on 1)

The method according to claim 1 comprising:
administering by inhalation to said patients a dose of at least 10 mg CBA twice a day for at least 12 months; and
reducing said frequency of said pulmonary exacerbations in said patients.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said patients are diagnosed with NCFB by computerized tomography (CT) or high resolution CT (HRCT).